Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4107 results

Sort By:

Avatar Contraception Communication Training

Study ID: NCT05995574
Start Date: 2025-07-01
End Date: 2030-06-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

166

Intervention / Treatment

avatar communication training

Sponsor

University of Texas Southwestern Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Quantified Evaluation of Noninvasive System Delivering Microwave Energy for Unwanted Fat Reduction and Skin Tightening in Asians.

Study ID: NCT06925074
Start Date: 2025-05
End Date: 2026-04
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

15

Intervention / Treatment
Sponsor

Chang Chang Cheng

Source: clinicaltrials.gov

Share:
Add to list

A Multifaceted Intervention on Reducing Immunization Errors

Study ID: NCT06745635
Start Date: 2025-07-03
End Date: 2026-12-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

72

Intervention / Treatment

Usual Care

Multifaceted intervention

Sponsor

Israelite Hospital Albert Einstein

Source: clinicaltrials.gov

Share:
Add to list

Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients

Study ID: NCT06911489
Start Date: 2025-07
End Date: 2027-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

116

Intervention / Treatment

68Ga-NRT6020 Injection

177Lu-NRT6020 Injection (stage 2)

177Lu-NRT6020 Injection (stage 3)

Sponsor

Chengdu New Radiomedicine Technology Co. LTD.

Source: clinicaltrials.gov

Share:
Add to list

Patiromer and Diet/hrQoL in Chronic Dialysis

Study ID: NCT06858280
Start Date: 2025-06-15
End Date: 2026-02
Study Type

Interventional

Study Phase

Phase3

No. of Participants

40

Intervention / Treatment

Patiromer 8400 Mug [Well

Placebo

Sponsor

Mario Negri Institute for Pharmacological Research

Source: clinicaltrials.gov

Share:
Add to list

Erector Spinae Block vs. Placebo Block Study

Study ID: NCT03978780
Start Date: 2025-06
End Date: 2027-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment

Erector spines Plane Block

Placebo Block

Sponsor

Women's College Hospital

Source: clinicaltrials.gov

Share:
Add to list

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

Study ID: NCT06574880
Start Date: 2025-05-01
End Date: 2026-09-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

45

Intervention / Treatment

LU-PSMA-617

5-fraction Stereotactic Body Radiation Therapy (SBRT)

Sponsor

Angela Y. Jia, MD PhD

Source: clinicaltrials.gov

Share:
Add to list

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Study ID: NCT06528691
Start Date: 2025-05
End Date: 2032-11
Study Type

Interventional

Study Phase

Phase2

No. of Participants

52

Intervention / Treatment

Entrectinib

Cyclophosphamide

Etoposide

Carboplatin

G-CSF

Freak

Surgery

Sponsor

St. Jude Children's Research Hospital

Source: clinicaltrials.gov

Share:
Add to list

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Study ID: NCT06317662
Start Date: 2025-04-26
End Date: 2028-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

171

Intervention / Treatment

Asparaginase Erwinia chrysanthemi

Biospecimen Collection

Blinatumomab

Bone Marrow Aspiration

CALASPARGASE PEGOL

Computed Tomography

Cyclophosphamide

Cytarabine

Etrorior

Dexamethasone

Doxorubicin

Echocardiography Test

FDG-Positron Emission Tomography

Leucovorin

Lumbar Puncture

Magnetic Resonance Imaging

Mercaptopurine

Methotrexate

Multigated Acquisition Scan

Pegaspargase

Prednisolone

Prednisone

Therapeutic Hydrocortisone

Thioguanine

Venetoclax

Vincristine

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

A First-in-Human Study of YL217 in Patients with Advanced Solid Tumors

Study ID: NCT06859762
Start Date: 2025-05
End Date: 2027-07
Study Type

Interventional

Study Phase

Phase1

No. of Participants

220

Intervention / Treatment

YL217 every 3 weeks (Q3W) intravenous (IV) infusion

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Source: clinicaltrials.gov

Share:
Add to list